PEB 6.16% 15.5¢ pacific edge limited ordinary shares

Analysts pick Pacific Edge to double in value

  1. 23 Posts.
    lightbulb Created with Sketch. 1
    A research note from Jarden has valued NZX-listed biotech Pacific Edge at double its current share price, citing the long-term commercial potential of its bladder cancer diagnostic technology, just need access to read full article - https://www.facebook.com/NBROnline/
 
watchlist Created with Sketch. Add PEB (NZSX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.